Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Puma Biotechnology Q2 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $49.20M Miss $50.75M Estimate

Author: Benzinga Newsdesk | August 07, 2025 04:27pm
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 45.63 percent. This is a 400 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $49.20 million which missed the analyst consensus estimate of $50.75 million by 3.05 percent. This is a 4.46 percent increase over sales of $47.10 million the same period last year.

Posted In: PBYI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist